DHIVY™ (carbidopa/levodopa) logo


Introducing DHIVY—
the first and only functionally fractionated CD/LD tablet for Parkinson's disease1,2

DHIVY tablet

DHIVY is a 25/100-mg
IR tablet of CD/LD1

DHIVY tablet split into segments

Scored with 4
fractionated segments1

Single segment of DHIVY tablet

Each segment contains
6.25/25 mg1

DHIVY offers a new way to individualize every dose to suit each patient's specific needs.1

Side view of enlarged DHIVY tablet

Images do not represent the actual size of the tablet.

CD/LD=carbidopa/levodopa; IR=immediate release.

Order samples of DHIVY for your practice

Co-pay support for your patients

Eligible patients may pay as little as $50 per 30-day fill.

Guide your patients to sign up now for DHIVY co-pay support.

There's more to come

Be the first to know about future developments, product availability, and other updates for DHIVY.

All fields are required.



DHIVY is contraindicated in patients

  • Currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine, linezolid, and tranylcypromine) or have recently (within 2 weeks) taken a nonselective MAO inhibitor. Hypertension can occur if these drugs are used concurrently.
  • With known hypersensitivity to any component of DHIVY.


Falling Asleep During Activities of Daily Living and Somnolence: Patients taking carbidopa/levodopa alone or with other dopaminergic drugs have reported suddenly falling asleep without prior warning of sleepiness while engaged in activities of daily living (including the operation of motor vehicles). Road traffic accidents attributed to sudden sleep onset have been reported. Sudden onset of sleep has been reported to occur more than one year after the initiation of treatment. Patients should be advised to exercise caution while driving or operating machines during treatment with DHIVY. Patients who have already experienced somnolence or an episode of sudden sleep onset should not participate in these activities during treatment with DHIVY. Before initiating treatment with DHIVY, advise patients about the potential to develop drowsiness and ask specifically about factors that may increase the risk for somnolence with DHIVY, such as the use of concomitant sedating medications and the presence of sleep disorders. Consider discontinuing DHIVY in patients who report significant daytime sleepiness or episodes of falling asleep during activities that require active participation.

Withdrawal-Emergent Hyperpyrexia and Confusion: A symptom complex that resembles neuroleptic malignant syndrome (characterized by elevated temperature, muscular rigidity, altered consciousness, and autonomic instability), with no other obvious etiology, has been reported in association with rapid dose reduction, withdrawal of, or changes in dopaminergic therapy. Avoid sudden discontinuation or rapid dose reduction in patients taking DHIVY. If the decision is made to discontinue DHIVY, the dose should be tapered to reduce the risk of hyperpyrexia and confusion.

Cardiovascular Ischemic Events: In patients with a history of myocardial infarction who have residual atrial, nodal, or ventricular arrhythmias, cardiac function should be monitored in an intensive cardiac care facility during the period of initial dosage adjustment.

Hallucinations/Psychotic-Like Behavior: Hallucinations and psychotic-like behavior have been reported with dopaminergic medications. In general, hallucinations present shortly after the initiation of therapy and may be responsive to dose reduction in levodopa. Patients with a major psychotic disorder should not be treated with DHIVY because of the risk of exacerbating psychosis. In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson's disease and may decrease the effectiveness of DHIVY.

Impulse Control/Compulsive Behaviors: Case reports suggest that patients can experience an intense urge to gamble, increased sexual urges, intense urges to spend money, binge eating, and/or other intense urges, and the inability to control these urges while taking one or more of the medications, including DHIVY, that increase central dopaminergic tone and that are generally used for the treatment of Parkinson’s disease. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to specifically ask patients or the caregivers about the development of new or increased gambling urges, sexual urges, uncontrolled spending, or other urges while being treated with DHIVY. Consider dosage reduction or stopping the medication if a patient develops such urges while taking DHIVY.

Dyskinesia: DHIVY can cause dyskinesias that may require a dosage reduction of DHIVY or other medications used for the treatment of Parkinson's disease.

Peptic Ulcer Disease: Treatment with DHIVY may increase the possibility of upper gastrointestinal hemorrhage in patients with a history of peptic ulcer.

Glaucoma: DHIVY may cause increased intraocular pressure in patients with glaucoma. Monitor intraocular pressure in patients with glaucoma after starting DHIVY.

Laboratory Tests: DHIVY may cause a positive Coombs test or false-positive reaction for urinary ketone bodies when a test tape is used for determination of ketonuria. This reaction will not be altered by boiling the urine specimen. False-negative tests may result with the use of glucose-oxidase methods of testing for glucosuria. Cases of falsely diagnosed pheochromocytoma in patients on carbidopa-levodopa therapy have been reported. Caution should be exercised when interpreting the plasma and urine levels of catecholamines and their metabolites in patients on carbidopa levodopa therapy.

Depression/Suicidality: All patients should be observed carefully for the development of depression with concomitant suicidal tendencies.

Drug Interactions: Monitor patients taking selective MAO-B inhibitors and DHIVY; this combination may be associated with severe orthostatic hypotension. Coadministration with dopamine D2 receptor antagonists, isoniazid, iron salts, or metoclopramide may reduce the effectiveness of DHIVY. Concurrent administration with antihypertensive drugs may result in postural hypotension, necessitating a dose reduction of the antihypertensive drug. Coadministration with dopamine-depleting agents is not recommended.

Adverse Reactions: The most common adverse reactions reported with carbidopa/levodopa tablets have included dyskinesias, such as choreiform, dystonic, and other involuntary movements, and nausea.

Please see full Prescribing Information.


DHIVY is a combination of carbidopa and levodopa indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.

References: 1. DHIVY. Package insert. Avion Pharmaceuticals, LLC; 2021. 2. SINEMET. Package insert. Merck Sharp & Dohme Corp.; 2020.